期刊
CURRENT PHARMACEUTICAL DESIGN
卷 19, 期 26, 页码 4701-4713出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612811319260004
关键词
MMP-2; MMP-3; MMP-13; rheumatoid arthritis; osteoarthritis; cancer; docking; zinc binding group
资金
- Research Corporation for Science Advancement
- Abbott Excellence in Chemistry Award
- Tripos, Inc.
- Gaussian, Inc.
This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据